EZH2 and myelodysplastic syndrome: In myeloid neoplasms, EZH2 mutations were identified in 10–13% of poor-prognosis myelodysplastic syndromes-myeloproliferative neoplasms, 6% of myelodysplastic syndromes, 6% of chronic myelomonocytic leukemia, and 1.7% of AML [13, 15–17].